Data from FDA - Curated by EPG Health - Last updated 09 February 2018

Indication(s)

1 INDICATIONS AND USAGE COPAXONE (glatiramer acetate injection) is indicated for the treatment of patients with relapsing forms of multiple sclerosis. COPAXONE is indicated for the treatment of patients with relapsing-forms of multiple sclerosis (1).

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Hereditary ATTR amyloidosis

Hereditary ATTR amyloidosis

Explore the pathophysiology, epidemiology and multi-system symptoms associated with hereditary ATTR amyloidosis, as well as how to achieve an early and accurate diagnosis.

EPNS 2019 Congress Highlights

EPNS 2019 Congress Highlights

The epgonline.org team is creating daily reports from the 13th European Paediatric Neurology Society (EPNS) Congress, held in Athens, Greece from 17th to 21st September 2019, to bring you coverage of cutting-edge science and advances in clinical care across all fields of paediatric neurology. 

Migraine Knowledge Centre

Migraine Knowledge Centre

The Migraine Knowledge Centre features latest research on the prevalence and impact of migraine, the proposed neurological basis of the condition (and how this is being translated into new and exciting drug therapies), as well as current patient care strategies collated from headache organisations worldwide.

Load more

Related Content

Advisory information

contraindications
4 CONTRAINDICATIONS COPAXONE is contraindicated in patients with known hypersensitivity to glatiramer acetate or mannitol. Known hypersensitivity to glatiramer acetate or mannitol (4)
Adverse reactions
6 ADVERSE REACTIONS The following serious adverse reactions are described elsewhere in the labeling: Post-Injection Reaction [see Warnings and Precautions (5.1)] Chest Pain [see Warnings and Precautions (5.2)] Lipoatrophy and Skin Necrosis [see Warnings and Precautions (5.3)] Potential Effects on Immune Response [see Warnings and Precautions (5.4)] In controlled studies of COPAXONE 20 mg/mL, most common adverse reactions (≥10% and ≥1.5 times higher than placebo) were: injection site reactions, vasodilatation, rash, dyspnea, and chest pain (6.1) In a controlled study of COPAXONE 40 mg/mL, most common adverse reactions (≥10% and ≥1.5 times higher than placebo) were: injection site reactions (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Teva Pharmaceuticals at 1-888-483-8279 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Incidence in Controlled Clinical Trials COPAXONE 20 mg per mL per day Among 563 patients treated with COPAXONE in blinded placebo-controlled trials, approximately 5% of the subjects discontinued treatment because of an adverse reaction. The adverse reactions most commonly associated with discontinuation were: injection site reactions, dyspnea, urticaria, vasodilatation, and hypersensitivity. The most common adverse reactions were: injection site reactions, vasodilatation, rash, dyspnea, and chest pain. Table 1 lists signs and symptoms that occurred in at least 2% of patients treated with COPAXONE 20 mg per mL in the placebo-controlled trials. These signs and symptoms were numerically more common in patients treated with COPAXONE than in patients treated with placebo. Adverse reactions were usually mild in intensity. Table 1: Adverse reactions in controlled clinical trials with an incidence ≥2% of patients and more frequent with COPAXONE (20 mg per mL daily) than with placebo COPAXONE 20 mg/mL (n=563) Placebo (n=564) Blood And Lymphatic System Disorders Lymphadenopathy 7% 3% Cardiac Disorders Palpitations 9% 4% Tachycardia 5% 2% Eye Disorders Eye Disorder 3% 1% Diplopia 3% 2% Gastrointestinal Disorders Nausea 15% 11% Vomiting 7% 4% Dysphagia 2% 1% General Disorders And Administration Site Conditions Injection Site Erythema 43% 10% Injection Site Pain 40% 20% Injection Site Pruritus 27% 4% Injection Site Mass 26% 6% Asthenia 22% 21% Pain 20% 17% Injection Site Edema 19% 4% Chest Pain 13% 6% Injection Site Inflammation 9% 1% Edema 8% 2% Injection Site Reaction 8% 1% Pyrexia 6% 5% Injection Site Hypersensitivity 4% 0% Local Reaction 3% 1% Chills 3% 1% Face Edema 3% 1% Edema Peripheral 3% 2% Injection Site Fibrosis 2% 1% Injection Site Atrophy* 2% 0% Immune System Disorders Hypersensitivity 3% 2% Infections And Infestations Infection 30% 28% Influenza 14% 13% Rhinitis 7% 5% Bronchitis 6% 5% Gastroenteritis 6% 4% Vaginal Candidiasis 4% 2% Metabolism And Nutrition Disorders Weight Increased 3% 1% Musculoskeletal And Connective Tissue Disorders Back Pain 12% 10% Neoplasms Benign, Malignant And Unspecified (Incl Cysts And Polyps) Benign Neoplasm of Skin 2% 1% Nervous System Disorders Tremor 4% 2% Migraine 4% 2% Syncope 3% 2% Speech Disorder 2% 1% Psychiatric Disorders Anxiety 13% 10% Nervousness 2% 1% Renal And Urinary Disorders Micturition Urgency 5% 4% Respiratory, Thoracic And Mediastinal Disorders Dyspnea 14% 4% Cough 6% 5% Laryngospasm 2% 1% Skin And Subcutaneous Tissue Disorders Rash 19% 11% Hyperhidrosis 7% 5% Pruritus 5% 4% Urticaria 3% 1% Skin Disorder 3% 1% Vascular Disorders Vasodilatation 20% 5% *Injection site atrophy comprises terms relating to localized lipoatrophy at injection site Adverse reactions which occurred only in 4 to 5 more subjects in the COPAXONE group than in the placebo group (less than 1% difference), but for which a relationship to COPAXONE could not be excluded, were arthralgia and herpes simplex. Laboratory analyses were performed on all patients participating in the clinical program for COPAXONE. Clinically-significant laboratory values for hematology, chemistry, and urinalysis were similar for both COPAXONE and placebo groups in blinded clinical trials. In controlled trials one patient discontinued treatment due to thrombocytopenia (16 x109/L), which resolved after discontinuation of treatment. Data on adverse reactions occurring in the controlled clinical trials of COPAXONE 20 mg per mL were analyzed to evaluate differences based on sex. No clinically-significant differences were identified. Ninety-six percent of patients in these clinical trials were Caucasian. The majority of patients treated with COPAXONE were between the ages of 18 and 45. Consequently, data are inadequate to perform an analysis of the adverse reaction incidence related to clinically-relevant age subgroups. Other Adverse Reactions In the paragraphs that follow, the frequencies of less commonly reported adverse clinical reactions are presented. Because the reports include reactions observed in open and uncontrolled premarketing studies (n= 979), the role of COPAXONE in their causation cannot be reliably determined. Furthermore, variability associated with adverse reaction reporting, the terminology used to describe adverse reactions, etc., limit the value of the quantitative frequency estimates provided. Reaction frequencies are calculated as the number of patients who used COPAXONE and reported a reaction divided by the total number of patients exposed to COPAXONE. All reported reactions are included except those already listed in the previous table, those too general to be informative, and those not reasonably associated with the use of the drug. Reactions are further classified within body system categories and enumerated in order of decreasing frequency using the following definitions: Frequent adverse reactions are defined as those occurring in at least 1/100 patients and infrequent adverse reactions are those occurring in 1/100 to 1/1,000 patients. Body as a Whole: Frequent: Abscess Infrequent: Injection site hematoma, moon face, cellulitis, hernia, injection site abscess, serum sickness, suicide attempt, injection site hypertrophy, injection site melanosis, lipoma, and photosensitivity reaction. Cardiovascular: Frequent: Hypertension. Infrequent: Hypotension, midsystolic click, systolic murmur, atrial fibrillation, bradycardia, fourth heart sound, postural hypotension, and varicose veins. Digestive: Infrequent: Dry mouth, stomatitis, burning sensation on tongue, cholecystitis, colitis, esophageal ulcer, esophagitis, gastrointestinal carcinoma, gum hemorrhage, hepatomegaly, increased appetite, melena, mouth ulceration, pancreas disorder, pancreatitis, rectal hemorrhage, tenesmus, tongue discoloration, and duodenal ulcer. Endocrine: Infrequent: Goiter, hyperthyroidism, and hypothyroidism. Gastrointestinal: Frequent: Bowel urgency, oral moniliasis, salivary gland enlargement, tooth caries, and ulcerative stomatitis. Hemic and Lymphatic: Infrequent: Leukopenia, anemia, cyanosis, eosinophilia, hematemesis, lymphedema, pancytopenia, and splenomegaly. Metabolic and Nutritional: Infrequent: Weight loss, alcohol intolerance, Cushing’s syndrome, gout, abnormal healing, and xanthoma. Musculoskeletal: Infrequent: Arthritis, muscle atrophy, bone pain, bursitis, kidney pain, muscle disorder, myopathy, osteomyelitis, tendon pain, and tenosynovitis. Nervous: Frequent: Abnormal dreams, emotional lability, and stupor. Infrequent: Aphasia, ataxia, convulsion, circumoral paresthesia, depersonalization, hallucinations, hostility, hypokinesia, coma, concentration disorder, facial paralysis, decreased libido, manic reaction, memory impairment, myoclonus, neuralgia, paranoid reaction, paraplegia, psychotic depression, and transient stupor. Respiratory: Frequent: Hyperventilation and hay fever. Infrequent: Asthma, pneumonia, epistaxis, hypoventilation, and voice alteration. Skin and Appendages: Frequent: Eczema, herpes zoster, pustular rash, skin atrophy, and warts. Infrequent: Dry skin, skin hypertrophy, dermatitis, furunculosis, psoriasis, angioedema, contact dermatitis, erythema nodosum, fungal dermatitis, maculopapular rash, pigmentation, benign skin neoplasm, skin carcinoma, skin striae, and vesiculobullous rash. Special Senses: Frequent: Visual field defect. Infrequent: Dry eyes, otitis externa, ptosis, cataract, corneal ulcer, mydriasis, optic neuritis, photophobia, and taste loss. Urogenital: Frequent: Amenorrhea, hematuria, impotence, menorrhagia, suspicious papanicolaou smear, urinary frequency, and vaginal hemorrhage. Infrequent: Vaginitis, flank pain (kidney), abortion, breast engorgement, breast enlargement, carcinoma in situ cervix, fibrocystic breast, kidney calculus, nocturia, ovarian cyst, priapism, pyelonephritis, abnormal sexual function, and urethritis. COPAXONE 40 mg per mL three times per week Among 943 patients treated with COPAXONE 40 mg per mL three times per week in a blinded, placebo-controlled trial, approximately 3% of the subjects discontinued treatment because of an adverse reaction. The most common adverse reactions were injection site reactions, which were also the most common cause of discontinuation. Table 2 lists signs and symptoms that occurred in at least 2% of patients treated with COPAXONE 40 mg per mL in the blinded, placebo-controlled trial. These signs and symptoms were numerically more common in patients treated with COPAXONE 40 mg per mL than in patients treated with placebo. Adverse reactions were usually mild in intensity. Table 2: Adverse reactions in a controlled clinical trial with an incidence ≥2% of patients and more frequent with COPAXONE (40 mg per mL three times per week) than with placebo COPAXONE 40 mg/mL (n=943) Placebo (n=461) General Disorders And Administration Site Conditions Injection Site Erythema 22% 2% Injection Site Pain 10% 2% Injection Site Mass 6% 0% Injection Site Pruritus 6% 0% Injection Site Edema 6% 0% Pyrexia 3% 2% Influenza-like Illness 3% 2% Injection Site Inflammation 2% 0% Chills 2% 0% Chest Pain 2% 1% Infections And Infestations Nasopharyngitis 11% 9% Respiratory Tract Infection Viral 3% 2% Respiratory, Thoracic and Mediastinal Disorders Dyspnea 3% 0% Vascular Disorders Vasodilatation 3% 0% Gastrointestinal Disorders Nausea 2% 1% Skin And Subcutaneous Tissue Disorders Erythema 2% 0% Rash 2% 1% No new adverse reactions appeared in subjects treated with COPAXONE 40 mg per mL three times per week as compared to subjects treated with COPAXONE 20 mg per mL per day in clinical trials and during postmarketing experience. Data on adverse reactions occurring in the controlled clinical trial of COPAXONE 40 mg per mL were analyzed to evaluate differences based on sex. No clinically significant differences were identified. Ninety-eight percent of patients in this clinical trial were Caucasian and the majority were between the ages of 18 and 50. Consequently, data are inadequate to perform an analysis of the adverse reaction incidence related to clinically-relevant age groups. 6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of COPAXONE. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Body as a Whole: sepsis; SLE syndrome; hydrocephalus; enlarged abdomen; allergic reaction; anaphylactoid reaction Cardiovascular System: thrombosis; peripheral vascular disease; pericardial effusion; myocardial infarct; deep thrombophlebitis; coronary occlusion; congestive heart failure; cardiomyopathy; cardiomegaly; arrhythmia; angina pectoris Digestive System: tongue edema; stomach ulcer; hemorrhage; liver function abnormality; liver damage; hepatitis; eructation; cirrhosis of the liver; cholelithiasis Hemic and Lymphatic System: thrombocytopenia; lymphoma-like reaction; acute leukemia Metabolic and Nutritional Disorders: hypercholesterolemia Musculoskeletal System: rheumatoid arthritis; generalized spasm Nervous System: myelitis; meningitis; CNS neoplasm; cerebrovascular accident; brain edema; abnormal dreams; aphasia; convulsion; neuralgia Respiratory System: pulmonary embolus; pleural effusion; carcinoma of lung Special Senses: glaucoma; blindness Urogenital System: urogenital neoplasm; urine abnormality; ovarian carcinoma; nephrosis; kidney failure; breast carcinoma; bladder carcinoma; urinary frequency

Usage information

Dosing and administration
2 DOSAGE AND ADMINISTRATION For subcutaneous injection only; doses are not interchangeable (2.1) COPAXONE 20 mg/mL per day (2.1) COPAXONE 40 mg/mL three times per week (2.1) Before use, allow the solution to warm to room temperature (2.2) 2.1 Recommended Dose COPAXONE is for subcutaneous use only. Do not administer intravenously. The dosing schedule depends on the product strength that is selected. The recommended doses are: COPAXONE 20 mg per mL: administer once per dayor COPAXONE 40 mg per mL: administer three times per week and at least 48 hours apart COPAXONE 20 mg per mL and COPAXONE 40 mg per mL are not interchangeable. 2.2 Instructions for Use Remove one blister-packaged prefilled syringe from the refrigerated carton. Let the prefilled syringe stand at room temperature for 20 minutes to allow the solution to warm to room temperature. Visually inspect the syringe for particulate matter and discoloration prior to administration. The solution in the syringe should appear clear, colorless to slightly yellow. If particulate matter or discoloration is observed, discard the syringe. Areas for subcutaneous self-injection include arms, abdomen, hips, and thighs. The prefilled syringe is for single use only. Discard unused portions.
Use in special populations
8 USE IN SPECIFIC POPULATIONS Nursing Mothers: It is not known if COPAXONE is excreted in human milk (8.3) Pediatric Use: The safety and effectiveness of COPAXONE have not been established in patients under 18 years of age (8.4) 8.1 Pregnancy Pregnancy Category B. Administration of glatiramer acetate by subcutaneous injection to pregnant rats and rabbits resulted in no adverse effects on offspring development. There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, COPAXONE should be used during pregnancy only if clearly needed. In rats or rabbits receiving glatiramer acetate by subcutaneous injection during the period of organogenesis, no adverse effects on embryo-fetal development were observed at doses up to 37.5 mg/kg/day (18 and 36 times, respectively, the therapeutic human dose of 20 mg/day on a mg/m2 basis). In rats receiving subcutaneous glatiramer acetate at doses of up to 36 mg/kg from day 15 of pregnancy throughout lactation, no significant effects on delivery or on offspring growth and development were observed. 8.2 Labor and Delivery The effects of COPAXONE on labor and delivery in pregnant women are unknown. 8.3 Nursing Mothers It is not known if glatiramer acetate is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when COPAXONE is administered to a nursing woman. 8.4 Pediatric Use The safety and effectiveness of COPAXONE have not been established in patients under 18 years of age. 8.5 Geriatric Use COPAXONE has not been studied in elderly patients. 8.6 Use in Patients with Impaired Renal Function The pharmacokinetics of glatiramer acetate in patients with impaired renal function have not been determined.
Pregnancy and lactation
8.3 Nursing Mothers It is not known if glatiramer acetate is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when COPAXONE is administered to a nursing woman.

Interactions

7 DRUG INTERACTIONS Interactions between COPAXONE and other drugs have not been fully evaluated. Results from existing clinical trials do not suggest any significant interactions of COPAXONE with therapies commonly used in MS patients, including the concurrent use of corticosteroids for up to 28 days. COPAXONE has not been formally evaluated in combination with interferon beta.

More information

Category Value
Authorisation number NDA020622
Agency product number 5M691HL4BO
Orphan designation No
Product NDC 68546-317,68546-325
Date Last Revised 29-01-2018
Type HUMAN PRESCRIPTION DRUG
Marketing authorisation holder Teva Neuroscience, Inc.